Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Quashie

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
F1000Research|January 9, 2023
Explaining the unexpected COVID-19 trends and potential impact across AfricaDaniel Oduro-Mensah, Ebenezer Oduro-Mensah, Peter Quashie, et al.
Journal of the International AIDS Society|November 14, 2014
The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compoundMark Wainberg, Kaitlin Anstett, Thibault Mesplede, et al.
Journal of the International AIDS Society|November 15, 2014
HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group MAgnès Depatureaux, Thibault Mesplède, Peter Quashie, et al.
Journal of Virological Methods|May 16, 2012
A high-throughput assay for HIV-1 integrase 3'-processing activity using time-resolved fluorescenceYing-Shan Han, Peter Quashie, Thibault Mesplede, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 29, 2015
HIV-1 Group O Resistance Against Integrase InhibitorsAgnès Depatureaux, Thibault Mesplède, Peter Quashie, et al.
The Journal of Antimicrobial Chemotherapy|October 5, 2014
Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistanceIsabelle Hardy, Bluma Brenner, Peter Quashie, et al.
Medrxiv : the Preprint Server for Health Sciences|June 30, 2025
SARS-CoV-2 antibody immunity across three continents: the West Africa, West Indies, West London ConsortiumDavid Greenwood, Oliver Hague, Eliza Mari Kwesi-Maliepaard, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
F1000Research|January 9, 2023
Explaining the unexpected COVID-19 trends and potential impact across AfricaDaniel Oduro-Mensah, Ebenezer Oduro-Mensah, Peter Quashie, et al.
Journal of the International AIDS Society|November 14, 2014
The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compoundMark Wainberg, Kaitlin Anstett, Thibault Mesplede, et al.
Journal of the International AIDS Society|November 15, 2014
HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group MAgnès Depatureaux, Thibault Mesplède, Peter Quashie, et al.
Journal of Virological Methods|May 16, 2012
A high-throughput assay for HIV-1 integrase 3'-processing activity using time-resolved fluorescenceYing-Shan Han, Peter Quashie, Thibault Mesplede, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 29, 2015
HIV-1 Group O Resistance Against Integrase InhibitorsAgnès Depatureaux, Thibault Mesplède, Peter Quashie, et al.
The Journal of Antimicrobial Chemotherapy|October 5, 2014
Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistanceIsabelle Hardy, Bluma Brenner, Peter Quashie, et al.
Medrxiv : the Preprint Server for Health Sciences|June 30, 2025
SARS-CoV-2 antibody immunity across three continents: the West Africa, West Indies, West London ConsortiumDavid Greenwood, Oliver Hague, Eliza Mari Kwesi-Maliepaard, et al.
Pageof 1